- Home
- DSY vs APLT Comparison
DSY vs APLT Comparison
Compare DSY & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- APLT
- Stock Information
- Founded
- DSY 2020
- APLT 2016
- Country
- DSY China
- APLT United States
- Employees
- DSY N/A
- APLT N/A
- Industry
- DSY
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- DSY
- APLT Health Care
- Exchange
- DSY Nasdaq
- APLT Nasdaq
- Market Cap
- DSY 58.8M
- APLT 80.3M
- IPO Year
- DSY N/A
- APLT 2019
- Fundamental
- Price
- DSY $1.04
- APLT $0.46
- Analyst Decision
- DSY
- APLT Buy
- Analyst Count
- DSY 0
- APLT 7
- Target Price
- DSY N/A
- APLT $6.10
- AVG Volume (30 Days)
- DSY 198.7K
- APLT 1.6M
- Earning Date
- DSY 02-10-2025
- APLT 05-08-2025
- Dividend Yield
- DSY N/A
- APLT N/A
- EPS Growth
- DSY 120.37
- APLT N/A
- EPS
- DSY 0.01
- APLT N/A
- Revenue
- DSY $7,323,356.00
- APLT N/A
- Revenue This Year
- DSY N/A
- APLT N/A
- Revenue Next Year
- DSY N/A
- APLT $2,426.33
- P/E Ratio
- DSY $83.61
- APLT N/A
- Revenue Growth
- DSY 16.37
- APLT N/A
- 52 Week Low
- DSY $0.75
- APLT $0.43
- 52 Week High
- DSY $13.47
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- DSY 35.13
- APLT 37.51
- Support Level
- DSY $0.98
- APLT $0.45
- Resistance Level
- DSY $1.19
- APLT $0.56
- Average True Range (ATR)
- DSY 0.15
- APLT 0.05
- MACD
- DSY 0.01
- APLT 0.01
- Stochastic Oscillator
- DSY 16.04
- APLT 5.38
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.